Copied
 
 
2023, EUR
24.04.2024
Bruttoresultat

12.836'

Primær drift

-19.833'

Årets resultat

22.442'

Aktiver

1.104''

Kortfristede aktiver

437''

Egenkapital

208''

Afkastningsgrad

-2 %

Soliditetsgrad

19 %

Likviditetsgrad

141 %

Resultat
24.04.2024
Årsrapport
2023
24.04.2024
2022
21.04.2023
2021
05.07.2022
2020
31.03.2021
2019
24.03.2020
2018
31.05.2019
2017
30.05.2018
2016
30.05.2017
2015
06.06.2016
Nettoomsætning3.664.0003.437.0001.361.0008.627.00013.878.00010.016.0008.611.0008.786.0009.826.000
Bruttoresultat12.836.00011.650.000-3.596.000000000
Resultat af primær drift-19.833.000-20.020.000-25.814.000-26.109.000-4.691.000-3.252.000-3.639.000-3.368.000-2.636.000
Indtægter af kapitalandele (tilknyttede og associerede) 000000000
Finansielle indtægter69.326.00014.079.000201.0003.268.0001.582.000841.0001.102.0001.218.0002.818.000
Finansieringsomkostninger000-3.609.000-1.707.000-701.000-1.195.000-1.591.000-3.239.000
Andre finansielle omkostninger-97.510.000-28.516.000-19.047.000000000
Resultat før skat12.579.00020.996.00020.563.00022.335.00034.118.00026.271.00021.138.0009.755.0008.903.000
Resultat22.442.00027.404.00028.690.00025.518.00034.737.00026.454.00021.881.00010.181.0009.120.000
Forslag til udbytte-5.000.0000-5.000.000-5.000.000-54.000.000-10.044.000-6.716.000-3.363.000-2.015.000
Aktiver
24.04.2024
Årsrapport
2023
24.04.2024
2022
21.04.2023
2021
05.07.2022
2020
31.03.2021
2019
24.03.2020
2018
31.05.2019
2017
30.05.2018
2016
30.05.2017
2015
06.06.2016
Kortfristede varebeholdninger14.146.00011.689.00010.918.00010.458.00017.480.0007.832.0007.024.0006.980.0006.812.000
Kortfristede tilgodehavender fra salg og tjenesteydelser 422.921.000296.428.00067.543.000136.362.00079.804.00051.100.00047.509.00072.069.00039.658.000
Likvider14.000497.00022.0007.0007.0007.0007.0007.0009.000
Kortfristede aktiver437.081.000308.614.00078.483.000146.827.00097.291.00058.939.00054.540.00079.056.00046.482.000
Immaterielle aktiver og goodwill17.529.00018.459.00018.316.00010.042.0002.951.0001.979.0001.933.0002.811.0003.676.000
Finansielle anlægsaktiver645.521.000692.725.000753.815.000193.378.000170.374.000135.351.000114.630.00098.550.000124.534.000
Materielle aktiver4.334.0004.661.0004.888.0002.859.0001.501.0001.429.0001.322.000424.000344.000
Langfristede aktiver667.384.000715.845.000777.019.000206.279.000174.826.000138.759.000117.885.000101.785.000128.554.000
Aktiver1.104.465.0001.024.459.000855.502.000353.106.000272.117.000197.698.000172.425.000180.841.000175.036.000
Aktiver
24.04.2024
Passiver
24.04.2024
Årsrapport
2023
24.04.2024
2022
21.04.2023
2021
05.07.2022
2020
31.03.2021
2019
24.03.2020
2018
31.05.2019
2017
30.05.2018
2016
30.05.2017
2015
06.06.2016
Forslag til udbytte5.000.00005.000.0005.000.00054.000.00010.044.0006.716.0003.363.0002.015.000
Egenkapital208.098.000188.947.000169.527.000148.963.000167.930.000135.963.000117.046.00098.485.00090.315.000
Hensatte forpligtelser6.592.00010.315.00010.407.0002.601.000531.000331.000334.000460.000610.000
Langfristet gæld til banker553.727.000557.212.000540.830.00014.303.00014.439.00012.428.00015.671.00023.539.0000
Anden langfristet gæld00653.00000000
Leverandører af varer og tjenesteydelser1.771.00014.619.00014.264.0002.957.000349.000457.000299.000505.000334.000
Kortfristede forpligtelser309.963.000241.900.000108.653.000186.586.00089.217.00048.976.00039.374.00058.357.00084.111.000
Gældsforpligtelser889.775.000825.197.000675.568.000201.542.000103.656.00061.404.00055.045.00081.896.00084.111.000
Forpligtelser889.775.000825.197.000675.568.000201.542.000103.656.00061.404.00055.045.00081.896.00084.111.000
Passiver1.104.465.0001.024.459.000855.502.000353.106.000272.117.000197.698.000172.425.000180.841.000175.036.000
Passiver
24.04.2024
Nøgletal
24.04.2024
Årsrapport
2023
24.04.2024
2022
21.04.2023
2021
05.07.2022
2020
31.03.2021
2019
24.03.2020
2018
31.05.2019
2017
30.05.2018
2016
30.05.2017
2015
06.06.2016
Afkastningsgrad -1,8 %-2,0 %-3,0 %-7,4 %-1,7 %-1,6 %-2,1 %-1,9 %-1,5 %
Dækningsgrad 350,3 %339,0 %-264,2 %Na.Na.Na.Na.Na.Na.
Resultatgrad 612,5 %797,3 %2.108,0 %295,8 %250,3 %264,1 %254,1 %115,9 %92,8 %
Varelagerets omsætningshastighed 0,3 0,3 0,1 0,8 0,8 1,3 1,2 1,3 1,4
Egenkapitals-forretning 10,8 %14,5 %16,9 %17,1 %20,7 %19,5 %18,7 %10,3 %10,1 %
Payout-ratio 22,3 %Na.17,4 %19,6 %155,5 %38,0 %30,7 %33,0 %22,1 %
Gældsdæknings-nøgletal Na.Na.Na.-723,4 %-274,8 %-463,9 %-304,5 %-211,7 %-81,4 %
Soliditestgrad 18,8 %18,4 %19,8 %42,2 %61,7 %68,8 %67,9 %54,5 %51,6 %
Likviditetsgrad 141,0 %127,6 %72,2 %78,7 %109,0 %120,3 %138,5 %135,5 %55,3 %
Resultat
24.04.2024
Gæld
24.04.2024
Årsrapport
24.04.2024
Nyeste:01.01.2023- 31.12.2023(offentliggjort: 24.04.2024)
Information om virksomhedens regnskabsklasse:This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act ​governing reporting class C enterprises (large). The accounting policies applied to these consolidated financial statements and parent financial statements are consistent with those applied last year. The annual report is presented in EUR.
Oplysning om pantsætninger og sikkerhedsstillelser:19 Assets charged and collateralThe entity has provided guarantees under which the guarantors assume joint and several liability for Group companies' net debt with bank and credit institution. Total net debt in relation to these guarantees amounts to EUR 99.7 million at 31 December 2023.
Beretning
24.04.2024
Dato for ledelsens godkendelse af årsrapporten:2024-02-27
Statement by Management on the annual report
Identifikation af den godkendte årsrapport:The Board of Directors and the Executive Board have today considered and approved the annual report of Orifarm Group A/S for the financial year 01. 01. 2023 - 31. 12. 2023.
Management's review
Beskrivelse af virksomhedens væsentligste aktiviteter:Primary activities Orifarm Group is a dynamic international player in the healthcare business. Our vision is to be no. 1 in making healthcare a better deal. Every day, we strive to make high quality pharmaceuticals at affordable prices available to end users by manufacturing, commercializing, and trading products. The Group's purpose is to provide as many people as possible with access to affordable quality medicine. We supply a wide range of high-quality pharmaceuticals across several therapeutic areas and stages of illness. Our portfolio covers pharmaceuticals for primary as well as secondary care by specialists, over the counter (OTC), and consumer healthcare products. It is our mission to challenge the market and make affordable, high-quality healthcare accessible. We want to create competition and provide important savings for society and to ensure better value for money for consumers while maintaining a high quality in our products. Orifarm Group operates on three product platforms: Pharma Trade Import, re-packaging and sales of medicine leveraging price arbitrages between countries; including medicines without an MA in a country (unlicensed) and comparator medicine for clinical trials. Specialty Rx Off-patent, small molecule medicine sold via pharmacy substitution and hospital tendering (nGx) or prescribed by physicians without substitution (pRx). Consumer Healthcare Products for health needs available without prescription; chosen by consumers; OTC regulated as pharmaceutical with an API, while VMS is regulated as food supplements (no API).
Vi bruger cookies til at øge oplevelsen og målrette vores markedsføring.
Ved at klikke OK tillader du brug af cookies. Læs mere her.
OK